LMRA Lumera Corpration (MM)

Lumera Corporation (NASDAQ: LMRA), a leader in the emerging field of nanotechnology, announced an interview with Dr. Charlie Campbell as the most recent installment of its 2007 Lumera Experts Podcasting Series. Campbell is a Professor of Chemistry and founding co-director of the Center of Nanotechnology at the University of Washington as well as a member of Lumera�s Scientific Advisory Board. The Department of Chemistry at the University of Washington is the third highest funded public institution in chemical research. As a faculty member, Dr. Campbell and others saw the need to converge their research on the nanoscale, which led to the founding of the Center of Nanotechnology. The Center has enabled better research and education in the field of nanotechnology, which is the wave of the future. �There are huge global issues that are pushing fast such as the fear of global warming and energy sources drying-up in the middle east, so there is a need to push for new energy sources in nanotechnology,� said Campbell in his podcast interview. �The research infrastructure for making new materials that occurred in the field of nanotechnology in about the past ten years will enable some very important technological breakthroughs in this area.� �Lumera is very fortunate to have Dr. Campbell as a member of Lumera�s Scientific Advisory Board, because of his leading expertise in nanotechnology,� commented Lumera Chief Executive Officer Tom Mino. �We are very excited about the progression in our products that are helping to speed research in many areas of science. We will continue to work closely with experts such as those featured in our podcast series, to ensure that our company stays at the forefront of this exciting field.� �Lumera is making exciting progress with their product that allows 1500 micro sensors to simultaneously interrogate and find solutions of chemical interests,� said Campbell in his podcast interview. �It promises to be a very powerful tool for future research and an area of importance for society�s impact on medicine.� Earlier this year, Lumera announced the 2007 Lumera Experts Podcast Series featuring interviews with industry leaders who are familiar with Lumera�s technology and are experts in nanotechnology, bio-arrays, drug discovery, electro-optics, and wireless technologies. Podcast interviews by the following individuals have all been previously featured as part of the series and are currently available to download on Lumera�s website: Dr. Niro Ramachandran, a research associate at the Harvard Institute of Proteomics led by Dr. Josh LaBaer Dr. Larry Dalton, a Professor of Chemistry and Electrical engineering at the University of Washington and Nobel Prize Nominee Dr. Joseph Vallner, recently President and CEO of Capnia Tom Mino, CEO of Lumera Dr. Sam Gambhir, professor of radiology and bioengineering, Director of the Molecular Imaging Program and head of the nuclear medicine division at Stanford University Dr. Jonathan Wells, Principal Partner at AJIS LLC, a broadband wireless technology consultancy and recently Director of Product Management and International Regulatory Affairs for GigaBeamhave The podcasts are available through a variety of distribution networks and can be downloaded among other places at podtech.com; Apple�s iTunes, Rocky Mountain Podcasting and at Lumera�s own website, http://www.lumera.com/Company/Podcasts.php. About Lumera Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com. Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.